T. Rowe Price Associates’s ImmunityBio IBRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $304K | Buy |
114,997
+48,896
| +74% | +$129K | ﹤0.01% | 2518 |
|
|
2025
Q1 | $199K | Buy |
66,101
+9,813
| +17% | +$29.5K | ﹤0.01% | 2638 |
|
|
2024
Q4 | $145K | Sell |
56,288
-18,959
| -25% | -$48.8K | ﹤0.01% | 2765 |
|
|
2024
Q3 | $281K | Sell |
75,247
-55,514
| -42% | -$207K | ﹤0.01% | 2504 |
|
|
2024
Q2 | $828K | Buy |
130,761
+6,882
| +6% | +$43.6K | ﹤0.01% | 1975 |
|
|
2024
Q1 | $667K | Buy |
123,879
+4,533
| +4% | +$24.4K | ﹤0.01% | 2088 |
|
|
2023
Q4 | $601K | Buy |
119,346
+8,834
| +8% | +$44.5K | ﹤0.01% | 2097 |
|
|
2023
Q3 | $187K | Sell |
110,512
-32,028
| -22% | -$54.2K | ﹤0.01% | 2520 |
|
|
2023
Q2 | $398K | Sell |
142,540
-24,218
| -15% | -$67.6K | ﹤0.01% | 2234 |
|
|
2023
Q1 | $304K | Buy |
166,758
+16,800
| +11% | +$30.6K | ﹤0.01% | 2337 |
|
|
2022
Q4 | $760K | Sell |
149,958
-7,908
| -5% | -$40.1K | ﹤0.01% | 1923 |
|
|
2022
Q3 | $785K | Buy |
157,866
+11,149
| +8% | +$55.4K | ﹤0.01% | 1879 |
|
|
2022
Q2 | $546K | Sell |
146,717
-18,404
| -11% | -$68.5K | ﹤0.01% | 2184 |
|
|
2022
Q1 | $926K | Sell |
165,121
-26,281
| -14% | -$147K | ﹤0.01% | 2040 |
|
|
2021
Q4 | $1.16M | Buy |
191,402
+9,300
| +5% | +$56.6K | ﹤0.01% | 1948 |
|
|
2021
Q3 | $1.77M | Sell |
182,102
-32,906
| -15% | -$321K | ﹤0.01% | 1780 |
|
|
2021
Q2 | $3.07M | Buy |
215,008
+12,070
| +6% | +$172K | ﹤0.01% | 1605 |
|
|
2021
Q1 | $4.82M | Buy |
+202,938
| New | +$4.82M | ﹤0.01% | 1473 |
|